LL-37
Human cathelicidin antimicrobial peptide LL-37
LL-37 is an antimicrobial peptide. A randomized trial examined only topical use for hard-to-heal venous leg ulcers.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
LL-37 is the defined 37-amino-acid peptide derived from human cathelicidin; the clinical source concerns only a topical investigational preparation.
- Human research
- Limited
- Replication
- Single research group
- Clinical endpoints
- Symptom- or function-related
- Safety
- Limited characterization
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
The overall trial population showed no significant healing advantage; dose-related subgroup findings are exploratory.
- Treatment with LL-37 peptide of hard-to-heal venous leg ulcers: a randomized placebo-controlled clinical trialHuman study2021
Grönberg A et al.
Accessed:
Research gaps
- ·Topical wound data must not be extrapolated to injections or systemic infection treatment. Independent confirmatory studies are absent.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
Besides antimicrobial properties, the study examined local wound biology; this does not establish a systemic mechanism.
- Treatment with LL-37 peptide of hard-to-heal venous leg ulcers: a randomized placebo-controlled clinical trialHuman study2021
Grönberg A et al.
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·The topical trial provides only limited local safety data. Systemic or injected use has not been adequately studied; absence of data is not evidence of safety. FDA notes insufficient safety information and nonclinical findings suggesting detrimental effects on male reproduction and possible protumorigenic effects in some tissues; this does not establish human risk, but is an unresolved safety concern.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·Topical wound data must not be extrapolated to injections or systemic infection treatment. Independent confirmatory studies are absent.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- FDA: certain bulk drug substances for use in compounding that may present significant safety risksRegulatory source2026
U.S. Food and Drug Administration
Accessed:
Sources
Sources checked: · Version 3
- Treatment with LL-37 peptide of hard-to-heal venous leg ulcers: a randomized placebo-controlled clinical trialHuman study2021
Grönberg A et al.
Accessed:
- FDA: certain bulk drug substances for use in compounding that may present significant safety risksRegulatory source2026
U.S. Food and Drug Administration
Accessed: